Loading stock…

Swedish Orphan Biovitrum AB (publ) (SOBI) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Swedish Orphan Biovitrum AB (publ)

SOBIMarket cap $15BPrice $43.4

Country🇸🇪Sweden

SectorHealthcare

IndustryBiotechnology

Develops treatments for rare diseases like hemophilia, immunology disorders, and specialty conditions that big pharma often ignores. Sobi's rare-disease focus lets it dominate niche markets where patient populations are small but treatment needs are life-critical.

In Bastion Portfolios?

52W Return+32%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+19%9

Revenue Forecast

Rev CAGR (1y)+8%5

Rev CAGR (3y)+13%8

Rev CAGR (5y)+10%8

Earnings Forecast

EPS Growth Y+1+1286%10

EPS Growth Y+2+25%8

EPS Growth Y+3+19%8

Quality

Margins

EBIT Margin31%9

Net Income Margin5%3

Free Cash Flow Margin26%9

Debt

Net Debt/EBITDA1.35

Efficiency

ROE3%2

ROA2%4

Earnings Stability55

GEAR+STRONG75

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)214

P/E Ratio (Forward 3y)145

P/BV3.64

EV Multiples

EV/EBITDA Fwd134

EV/EBIT Fwd184

Yield

Free Cash Flow Yield5.2%6

Dividend Yieldna–

Momentum

Short term

1 month return-4%6

3 month return-8%4

YTD return+31%9

Mid term

Price vs 52wHigh89%8

1 year return+39%8

Long term

3 year return+94%7

5 year return+94%7

Risk Shield

Price Risk

Beta0.85

Volatility27%8

Free Cash Flow

Free Cash Flow Margin26%9

Free Cash Flow Yield5.2%6

Quality

ROCE16%8

Earnings Stability55

Net Debt/EBITDA1.35

02Growth

Is it actually growing, and how fast?

SOBISwedish Orphan Biovitrum AB (publ)

Revenue FY25$3.0B

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+19%9

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+13%8

Revenue, next 5Y, CAGR+10%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+1286%10

EPS growth, FY27E+25%8

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 19%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 13%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 10%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 25%/yr vs revenue 13%/yr), so margins should widen.

WATCH

Revenue grew 19%/yr over the last 3 years; forecasts see it cooling to 13%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

SOBISwedish Orphan Biovitrum AB (publ)

Total return Current292%

Price return Current292%

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-8%4

YTD return+31%9

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+39%8

3-year return+94%7

5-year return+94%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +94% over three years and +94% over five, ahead of 60% of the market.

It's up 39% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+31%).

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-8%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on SOBI. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SOBISwedish Orphan Biovitrum AB (publ)

Revenue FY25$3.0B

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+19%9

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+13%8

Revenue, next 5Y, CAGR+10%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+1286%10

EPS growth, FY27E+25%8

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 19%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 13%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 10%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 25%/yr vs revenue 13%/yr), so margins should widen.

WATCH

Revenue grew 19%/yr over the last 3 years; forecasts see it cooling to 13%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

SOBISwedish Orphan Biovitrum AB (publ)

Total return Current292%

Price return Current292%

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-8%4

YTD return+31%9

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+39%8

3-year return+94%7

5-year return+94%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +94% over three years and +94% over five, ahead of 60% of the market.

It's up 39% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+31%).

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-8%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on SOBI. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community